Piercarlo Sarzi-Puttini

Summary

Country: Italy

Publications

  1. ncbi The characteristics of symptomatic osteoarthritis in general and specialist practice in Italy: design and methods of the AMICA Study
    Fabio Parazzini
    Division of Epidemiology, Istituto Mario Negri, Milan, Italy
    Semin Arthritis Rheum 35:11-6. 2005
  2. doi Multidisciplinary approach to fibromyalgia: what is the teaching?
    Piercarlo Sarzi-Puttini
    Rheumatology Unit, L Sacco University Hospital, Ospedale L Sacco, Via GB Grassi 74, Milan, Italy
    Best Pract Res Clin Rheumatol 25:311-9. 2011
  3. ncbi Efficacy of ketoprofen vs. ibuprofen and diclofenac: a systematic review of the literature and meta-analysis
    Piercarlo Sarzi-Puttini
    Rheumatology Unit, L Sacco University Hospital, Milan, Italy
    Clin Exp Rheumatol 31:731-8. 2013
  4. ncbi Dysfunctional syndromes and fibromyalgia: a 2012 critical digest
    Piercarlo Sarzi-Puttini
    Rheumatology Unit, L Sacco University Hospital, Milan, Italy
    Clin Exp Rheumatol 30:143-51. 2012
  5. doi Interleukin 6 blockade: tocilizumab in psoriatic arthritis
    Fabiola Atzeni
    Experimental Medicine, Queen Mary University of London, London, UK
    J Rheumatol Suppl 89:97-9. 2012
  6. doi Chronic widespread pain: from peripheral to central evolution
    Piercarlo Sarzi-Puttini
    Rheumatology Unit, L Sacco University Hospital, Milan, Italy
    Best Pract Res Clin Rheumatol 25:133-9. 2011
  7. pmc Central motor control failure in fibromyalgia: a surface electromyography study
    Roberto Casale
    Department of Clinical Neurophysiology and Pain Rehabilitation Unit, Salvatore Maugeri Foundation, IRCCS, Scientific Institute of Montescano, Montescano PV, Italy
    BMC Musculoskelet Disord 10:78. 2009
  8. pmc B lymphocyte intestinal homing in inflammatory bowel disease
    Caterina Defendenti
    Laboratory Unit, Fatebenefratelli Hospital, Milan, Italy
    BMC Immunol 12:71. 2011
  9. ncbi Osteoarthritis: an overview of the disease and its treatment strategies
    Piercarlo Sarzi-Puttini
    Division of Rheumatology, L Sacco University Hospital, Milan, Italy
    Semin Arthritis Rheum 35:1-10. 2005
  10. ncbi Do physicians treat symptomatic osteoarthritis patients properly? Results of the AMICA experience
    Piercarlo Sarzi-Puttini
    Rheumatology Unit, L Sacco University Hospital, Milan, Italy
    Semin Arthritis Rheum 35:38-42. 2005

Detail Information

Publications118 found, 100 shown here

  1. ncbi The characteristics of symptomatic osteoarthritis in general and specialist practice in Italy: design and methods of the AMICA Study
    Fabio Parazzini
    Division of Epidemiology, Istituto Mario Negri, Milan, Italy
    Semin Arthritis Rheum 35:11-6. 2005
    ..The diagnostic and clinical approach to osteoarthritis (OA) of the hand, knee, and hip in general practice and specialist practice in Italy as determined by the AMICA project...
  2. doi Multidisciplinary approach to fibromyalgia: what is the teaching?
    Piercarlo Sarzi-Puttini
    Rheumatology Unit, L Sacco University Hospital, Ospedale L Sacco, Via GB Grassi 74, Milan, Italy
    Best Pract Res Clin Rheumatol 25:311-9. 2011
    ..Physical exercise and multimodal cognitive behavioural therapy are the most widely accepted and beneficial forms of non-pharmacological therapy...
  3. ncbi Efficacy of ketoprofen vs. ibuprofen and diclofenac: a systematic review of the literature and meta-analysis
    Piercarlo Sarzi-Puttini
    Rheumatology Unit, L Sacco University Hospital, Milan, Italy
    Clin Exp Rheumatol 31:731-8. 2013
    ..The aim of this systematic review of the literature and meta-analysis of randomised controlled trials (RCTs) was to compare the efficacy of orally administered ketoprofen with that of ibuprofen and/or diclofenac...
  4. ncbi Dysfunctional syndromes and fibromyalgia: a 2012 critical digest
    Piercarlo Sarzi-Puttini
    Rheumatology Unit, L Sacco University Hospital, Milan, Italy
    Clin Exp Rheumatol 30:143-51. 2012
    ..This review will discuss the recent literature concerning the most common dysfunctional disorders: fibromyalgia syndrome, myalgic encephalomyelitis/chronic fatigue syndrome, and irritable bowel syndrome...
  5. doi Interleukin 6 blockade: tocilizumab in psoriatic arthritis
    Fabiola Atzeni
    Experimental Medicine, Queen Mary University of London, London, UK
    J Rheumatol Suppl 89:97-9. 2012
    ....
  6. doi Chronic widespread pain: from peripheral to central evolution
    Piercarlo Sarzi-Puttini
    Rheumatology Unit, L Sacco University Hospital, Milan, Italy
    Best Pract Res Clin Rheumatol 25:133-9. 2011
    ..The two models (neurochemical and biopsychosocial) also affect our ability to find therapeutic answers...
  7. pmc Central motor control failure in fibromyalgia: a surface electromyography study
    Roberto Casale
    Department of Clinical Neurophysiology and Pain Rehabilitation Unit, Salvatore Maugeri Foundation, IRCCS, Scientific Institute of Montescano, Montescano PV, Italy
    BMC Musculoskelet Disord 10:78. 2009
    ..The aim of this study was to assess whether the myoelectrical manifestations of fatigue in patients affected by FM are central or peripheral in origin...
  8. pmc B lymphocyte intestinal homing in inflammatory bowel disease
    Caterina Defendenti
    Laboratory Unit, Fatebenefratelli Hospital, Milan, Italy
    BMC Immunol 12:71. 2011
    ..The objective is to investigate the localisation of immunoglobulin-producing cells (IPCs) in samples of inflamed intestinal tissue taken from patients with IBD, and their possible relationship with clinical features...
  9. ncbi Osteoarthritis: an overview of the disease and its treatment strategies
    Piercarlo Sarzi-Puttini
    Division of Rheumatology, L Sacco University Hospital, Milan, Italy
    Semin Arthritis Rheum 35:1-10. 2005
    ..The disease course and patient's requirements often change over time, thus requiring a periodic review and readjustment of therapy rather than the rigid continuation of a single treatment...
  10. ncbi Do physicians treat symptomatic osteoarthritis patients properly? Results of the AMICA experience
    Piercarlo Sarzi-Puttini
    Rheumatology Unit, L Sacco University Hospital, Milan, Italy
    Semin Arthritis Rheum 35:38-42. 2005
    ..The study was designed to evaluate their prescription modalities to determine whether they matched the recently proposed treatment guidelines for OA (ACR 2000; EULAR 2000; APS 2002)...
  11. ncbi Pain and ketoprofen: what is its role in clinical practice?
    P Sarzi-Puttini
    Rheumatology Unit, L Sacco University Hospital, Milan, Italy
    Reumatismo 62:172-88. 2010
    ....
  12. ncbi [Complementary medicine in rheumatoid arthritis]
    P Sarzi-Puttini
    Unita di Reumatologia, Università Ospedale L Sacco, Via G B Grassi 74, 20157 Milano, Italia
    Reumatismo 57:226-31. 2005
    ....
  13. ncbi Autoimmunity and anti-TNF-alpha agents
    Fabiola Atzeni
    Rheumatology Unit, Department of Rheumatology, University Hospital L Sacco, Via GB Grassi 74, 20157 Milan, Italy
    Ann N Y Acad Sci 1051:559-69. 2005
    ..3% and in 12.9% of adalimumab-treated RA patients. Only limited data on the induction of aPL antibodies during TNF-alpha blocking treatment are available...
  14. doi Cardiac involvement in systemic rheumatic diseases: An update
    Piercarlo Sarzi-Puttini
    L Sacco University Hospital, Milan, Italy
    Autoimmun Rev 9:849-52. 2010
    ..As these are all associated with an unfavourable prognosis, it is essential to detect subclinical cardiac involvement in asymptomatic SAD patients, and begin adequate management and treatment early...
  15. ncbi Environment and systemic lupus erythematosus: an overview
    Piercarlo Sarzi-Puttini
    Rheumatology Unit, Department of Rheumatology, L Sacco University Hospital, Milan, Italy
    Autoimmunity 38:465-72. 2005
    ..A better understanding of the etiopathogenetic mechanism of SLE is required in order to clarify the multiple interactions between environmental exposures and genetic factors...
  16. ncbi Tumor necrosis factor-alpha, biologic agents and cardiovascular risk
    P Sarzi-Puttini
    Rheumatology Unit, L Sacco University Hospital, Milan, Italy
    Lupus 14:780-4. 2005
    ..Due to the lack of evidence of a beneficial effect of anti-TNF-alpha agents in treatment of CHF, they should not be used to treat patients with New York Heart Association (NYHA) class III or IV heart failure...
  17. ncbi Osteoarthritis of the spine
    Piercarlo Sarzi-Puttini
    Rheumatology Unit, L Sacco University Hospital, Milan, Italy
    Semin Arthritis Rheum 34:38-43. 2005
  18. ncbi TNF-alpha, rheumatoid arthritis, and heart failure: a rheumatological dilemma
    Piercarlo Sarzi-Puttini
    Rheumatology Unit, University Hospital L Sacco, Via GB Grassi 74, 20157 Milan, Italy
    Autoimmun Rev 4:153-61. 2005
    ....
  19. ncbi Increased neural sympathetic activation in fibromyalgia syndrome
    Piercarlo Sarzi-Puttini
    Rheumatology Unit, L Sacco University Hospital, Via GB Grassi 74, 20157 Milano, Italy
    Ann N Y Acad Sci 1069:109-17. 2006
    ..This review discusses the general aspects of the altered HPA and ANS, sympathetic overactivity, and alterations in cardiovascular autonomic responses to gravitational stimuli...
  20. ncbi New developments in our understanding of DISH (diffuse idiopathic skeletal hyperostosis)
    Piercarlo Sarzi-Puttini
    Rheumatology Unit, University Hospital L Sacco, Via GB Grassi 74, 20157 Milan, Italy
    Curr Opin Rheumatol 16:287-92. 2004
    ..Purpose of this review is to summarize new clinical, pathogenetic and therapeutic insights of this disease...
  21. doi Anti-polymer antibodies are correlated with pain and fatigue severity in patients with fibromyalgia syndrome
    Piercarlo Sarzi-Puttini
    Rheumatology Unit, L Sacco University Hospital, Milan, Italy
    Autoimmunity 41:74-9. 2008
    ..To investigate the prevalence of antipolymer antibody (APA) in patients with fibromyalgia (FM) and to examine its association with FM severity symptoms...
  22. ncbi Treatment strategy in fibromyalgia syndrome: where are we now?
    Piercarlo Sarzi-Puttini
    Clinical Research Scientist, Rheumatology Unit, L Sacco University Hospital, Milan, Italy
    Semin Arthritis Rheum 37:353-65. 2008
    ..The treatment of the fibromyalgia syndrome (FMS) is not standardized and often ineffective, and the course of disease progression is unpredictable...
  23. ncbi Fibromyalgia syndrome: the pharmacological treatment options
    P Sarzi-Puttini
    Rheumatology Unit, L Sacco University Hospital, Milan, Italy
    Reumatismo 60:50-8. 2008
    ..The nature of FM suggests that an individualized, multimodal approach that includes both pharmacologic and nonpharmacologic therapies seems to be the most appropriate treatment strategy to date...
  24. ncbi Efficacy and safety of anti-TNF agents in the Lombardy rheumatoid arthritis network (LORHEN)
    P Sarzi-Puttini
    Rheumatology Unit, L Sacco University Hospital, Milan, Italy
    Reumatismo 60:290-5. 2008
    ....
  25. ncbi An open, randomized comparison study of cyclosporine A, cyclosporine A + methotrexate and cyclosporine A + hydroxychloroquine in the treatment of early severe rheumatoid arthritis
    Piercarlo Sarzi-Puttini
    Unità Operativa di Reumatologia, University Hospital L Sacco, Via G B Grassi 74, 20157 Milan, Italy
    Rheumatol Int 25:15-22. 2005
    ....
  26. ncbi Infliximab-induced lupus in Crohn's disease: a case report
    P Sarzi-Puttini
    Rheumatology Unit, L Sacco University Hospital, Milan, Italy
    Dig Liver Dis 35:814-7. 2003
    ..This is the first case, to our knowledge, of onset of prolonged infliximab-induced lupus...
  27. ncbi The Italian version of the Fibrofatigue Scale, a reliable tool for the evaluation of fibromyalgia symptoms
    P Sarzi-Puttini
    Department of Rheumatology, University Hospital L Sacco, Via GB Grassi, 20157 Milan, Italy
    J Psychosom Res 56:213-6. 2004
    ..To validate a translated Italian version of the Fibrofatigue Scale (FFS)...
  28. doi Cardiovascular involvement in psoriatic arthritis
    F Atzeni
    Rheumatology Unit, L Sacco University Hospital, Milan, Italy
    Reumatismo 63:148-54. 2011
    ..Active PsA is a risk factor for CVD, and so PsA patients should be screened for subclinical forms of the disease and its risk factors, and an early treatment approach should be adopted...
  29. doi Predicting response to anti-TNF treatment in rheumatoid arthritis patients
    Fabiola Atzeni
    Rheumatology Unit, L Sacco University Hospital, Milan, Italy
    Autoimmun Rev 8:431-7. 2009
    ..To identify the clinical factors predicting failure or a good clinical response in the cohort of RA patients entered in the Lombardy Rheumatology Network (LORHEN) registry after 3 years of treatment with anti-TNF agents...
  30. doi Switching TNF-alpha antagonists in rheumatoid arthritis: the experience of the LORHEN registry
    Roberto Caporali
    Division of Rheumatology, University of Pavia, IRCCS Policlinico S Matteo Foundation, Pavia, Italy
    Autoimmun Rev 9:465-9. 2010
    ..The patients with higher disease activity levels and those stopping the first anti-TNFalpha treatment because of a lack of efficacy are very likely to respond to the second treatment...
  31. doi Unusual B cell morphology in inflammatory bowel disease
    Caterina Defendenti
    Laboratory Unit, Fatebenefratelli Hospital, Milan, Italy
    Pathol Res Pract 208:387-91. 2012
    ....
  32. doi Serious infections during anti-TNFalpha treatment in rheumatoid arthritis patients
    Ennio Giulio Favalli
    UOC Day Hospital of Rheumatology, G Pini Orthopedic Institute, University of Milan, Milan, Italy
    Autoimmun Rev 8:266-73. 2009
    ..014), and the concomitant use of corticosteroids (p=0.029) as significant predictors of infections. There was no statistically significant difference in risk between the anti-TNFalpha agents...
  33. doi TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice
    Antonio Marchesoni
    Day Hospital of Rheumatology, G Pini Orthopaedic Institute, Milan, Italy
    Ann N Y Acad Sci 1173:837-46. 2009
    ..Comorbidities, increasing DAS28 values and co-therapy with methotrexate were associated with a lower risk of discontinuation...
  34. ncbi Long-term prognosis and causes of death in systemic lupus erythematosus
    Andrea Doria
    Division of Rheumatology, Department of Clinical and Experimental Medicine, University of Padova, Italy
    Am J Med 119:700-6. 2006
    ..We studied survival rate, prognostic factors, and causes of death in patients with systemic lupus erythematosus (SLE), particularly focusing on the influence of disease severity...
  35. doi The heart in rheumatoid arthritis
    Maurizio Turiel
    Cardiology Unit, Dipartimento di Tecnologie per la Salute, IRCCS Orthopedic Galeazzi Institute, University of Milan, Milan, Italy
    Autoimmun Rev 9:414-8. 2010
    ..As these are all associated with an unfavourable prognosis, it is essential to detect subclinical cardiac involvement in still asymptomatic RA patients in order to assure adequate long-term treatment...
  36. doi Anti-thyroid antibodies and thyroid dysfunction in rheumatoid arthritis: prevalence and clinical value
    Fabiola Atzeni
    Rheumatology Unit, L Sacco University Hospital, Milan, Italy
    Autoimmunity 41:111-5. 2008
    ..The aim of this study was to assess thyroid function as well as the prevalence and clinical value of anti-thyroid antibodies in patients with rheumatoid arthritis (RA)...
  37. doi CC chemokine receptor 5 polymorphism in Italian patients with Behcet's disease
    Fabiola Atzeni
    Rheumatology Unit, L Sacco University Hospital, Milan, Italy
    Rheumatology (Oxford) 51:2141-5. 2012
    ..To evaluate the potential role of CC chemokine receptor 5 (CCR5)Δ32 polymorphism in the susceptibility to and clinical expression of Behçet's disease (BD) in a cohort of Italian patients...
  38. pmc Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis
    Franco Capsoni
    Department of Internal Medicine, Ospedale Maggiore Policlinico, IRCCS, University of Milan, Milan, Italy
    Arthritis Res Ther 7:R250-5. 2005
    ....
  39. doi Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry
    Fabiola Atzeni
    Rheumatology Unit, L Sacco University Hospital, Milan, Italy
    Autoimmun Rev 12:225-9. 2012
    ..To evaluate the risk of serious infections (SIs) in RA patients receiving anti-TNF therapy on the basis of the data included in the GISEA register...
  40. doi Silent cardiovascular involvement in patients with diffuse systemic sclerosis: a controlled cross-sectional study
    Maurizio Turiel
    IRCCS Galeazzi Orthopedic Institute, University of Milan, Milan, Italy
    Arthritis Care Res (Hoboken) 65:274-80. 2013
    ..The aim of this pilot study was to use various endothelial and atherosclerosis markers to identify early cardiovascular involvement in a group of SSc patients...
  41. ncbi Abnormalities of cardiovascular neural control and reduced orthostatic tolerance in patients with primary fibromyalgia
    Raffaello Furlan
    Department of Internal Medicine II, Ospedale L Sacco, Universita degli Studi di Milano, Milano, Italy
    J Rheumatol 32:1787-93. 2005
    ..We tested the hypothesis that FM is characterized by sympathetic overactivity and alterations in cardiovascular autonomic response to gravitational stimulus...
  42. doi Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal
    Roberto Caporali
    Rheumatology Unit, University of Pavia, IRCCS Policlinico S Matteo Foundation, 27100 Pavia, Italy
    Autoimmun Rev 8:274-80. 2009
    ..As the first published registry of anti-TNFalpha-treated patients in Italy, Lombardy Rheumatology Network (LORHEN) is already making its contribution in this direction...
  43. pmc Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study
    Fabiola Atzeni
    Rheumatology Unit, Department of Medicine, L Sacco University Hospital, 74 Via GB Grassi, 20157 Milano, Italy
    Arthritis Res Ther 8:R3. 2006
    ..Antinuclear and anti-dsDNA autoantibodies, but not anti-phospholipid autoantibodies, can be induced by adalimumab but to a lower extent than in studies with other anti-TNF blocking agents...
  44. doi Organ-specific autoantibodies in patients with rheumatoid arthritis treated with adalimumab: a prospective long-term follow-up
    Fabiola Atzeni
    Rheumatology Unit, L Sacco University Hospital, Milan, Italy
    Autoimmunity 41:87-91. 2008
    ..Aim of our study was to assess the prevalence and concentration of a panel of organ-specific autoantibodies in patients with RA and to evaluate their relationship with clinical manifestations and treatment efficacy...
  45. ncbi Potential target of infliximab in autoimmune and inflammatory diseases
    Fabiola Atzeni
    Rheumatology Unit, L Sacco Hospital, University of Milan, Via GB Grassi 74, 20157 Milan, Italy
    Autoimmun Rev 6:529-36. 2007
    ..A number of other more rare disorders also may be responsive to TNF blockade. We here review the current and prospective roles of infliximab in the treatment of autoimmune diseases and other conditions...
  46. ncbi Long-term safety and efficacy of low-dose cyclosporin A in severe psoriatic arthritis
    Piercarlo Sarzi-Puttini
    Rheumatology Unit, University Hospital L Sacco, Milan, Italy
    Rheumatol Int 21:234-8. 2002
    ..The aim of this study was to evaluate the efficacy and tolerability of long-term treatment with cyclosporin A (CsA) in patients with psoriatic arthritis (PsA)...
  47. doi Chronic widespread pain in the spectrum of rheumatological diseases
    Fabiola Atzeni
    Rheumatology Unit, L Sacco University Hospital, Milan, Italy
    Best Pract Res Clin Rheumatol 25:165-71. 2011
    ..A misdiagnosis harms the patients and the community. Rheumatologists should be able to recognise and distinguish primary and secondary FM, and need new guidelines and instruments to avoid making mistakes...
  48. ncbi What is the role of rituximab in the treatment of rheumatoid arthritis?
    Fabiola Atzeni
    Rheumatology Unit, L Sacco University Hospital, Via GB Grassi 74, 20157 Milan, Italy
    Autoimmun Rev 6:553-8. 2007
    ....
  49. doi Usefulness of cardiovascular biomarkers and cardiac imaging in systemic rheumatic diseases
    Fabiola Atzeni
    L Sacco University Hospital, Milan, Italy
    Autoimmun Rev 9:845-8. 2010
    ..Furthermore, plasma ADMA levels could be used as a simple means of screening SRD patients at higher CV risk who need more aggressive treatment aimed at slowing or reversing the progression of atherosclerosis...
  50. doi Cardiovascular injury in systemic autoimmune diseases: an update
    Maurizio Turiel
    Department of Health Technologies, Cardiology Unit, IRCCS Orthopedic Galeazzi Institute, University of Milan, Via R Galeazzi 4, Milan, Italy
    Intern Emerg Med 6:99-102. 2011
    ..Moreover, chronic inflammation, accelerated atherosclerosis and functional abnormalities of the endothelium suggest a subclinical CV involvement beginning rapidly soon after the onset of the disease and progressing with disease duration...
  51. ncbi Polymyositis-dermatomyositis and infections
    Sandra Zampieri
    University of Padova, Division of Rheumatology, Department of Clinical and Experimental Medicine, Italy
    Autoimmunity 39:191-6. 2006
    ..In this review, the increased risk of developing infections in these patients is also underlined and published data are reported...
  52. doi Neuroendocrine therapy of fibromyalgia syndrome: an update
    Piercarlo Sarzi-Puttini
    Rheumatology Unit, University Hospital L Saccco, Milan, Italy
    Ann N Y Acad Sci 1193:91-7. 2010
    ..Studies predicting treatment response indicate that it is useful if not essential to tailor the choice of treatment components to the needs of individual patients...
  53. ncbi Potential off-label use of infliximab in autoimmune and non-autoimmune diseases: a review
    Fabiola Atzeni
    Rheumatology Unit, L Sacco University Hospital, Via GB Grassi 74, 20157 Milan, Italy
    Autoimmun Rev 4:144-52. 2005
    ..We here review the current and prospective roles of infliximab in the treatment of autoimmune diseases and other conditions that do not currently have FDA or EMEA approval...
  54. pmc Morphological distribution of μ chains and cd15 receptors in colorectal polyp and adenocarcinoma specimens
    Caterina Defendenti
    Laboratory Unit and Divisions of Fatebenefratelli Hospital, Milan, Italy
    BMC Clin Pathol 13:8. 2013
    ..The aim of the study was to analyse variations in IPCs and CD15+ cell morphology or distribution in bowel biopsy specimens taken from patients with pre-malignant polyps or adenocarcinomas...
  55. pmc Biomarkers of good EULAR response to the B cell depletion therapy in all seropositive rheumatoid arthritis patients: clues for the pathogenesis
    Gianfranco Ferraccioli
    Division of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy
    PLoS ONE 7:e40362. 2012
    ....
  56. ncbi Complementary treatment in fibromyalgia: combination of somatic and abdominal acupuncture
    Cristina Iannuccelli
    Rheumatology Unit, Department of Internal Medicine, Sapienza University of Rome, Rome, Italy
    Clin Exp Rheumatol 30:112-6. 2012
    ..As a result, acupuncture could be very useful to relieve pain in a multidisciplinary setting...
  57. pmc Anti-cyclic citrullinated peptide antibodies in primary Sjögren syndrome may be associated with non-erosive synovitis
    Fabiola Atzeni
    Rheumatology Unit, L, Sacco Hospital, University of Milan, Via G, B, Grassi 74, 20127 Milan, Italy
    Arthritis Res Ther 10:R51. 2008
    ..The purpose of this study was to investigate the prevalence of cyclic citrullinated peptide antibodies (anti-CCP) in patients with primary Sjögren syndrome (pSS) and its correlation with clinical and laboratory data...
  58. doi Cardiovascular involvement in systemic autoimmune diseases
    Simona Sitia
    IRCCS Orthopedic Galeazzi Institute, University of Milan, Department of Health Technologies, Cardiology Unit, Milan, Italy
    Autoimmun Rev 8:281-6. 2009
    ....
  59. ncbi The role of echocardiographic techniques in connective tissue diseases
    Maurizio Turiel
    Department of Cardiology, Istituto Galeazzi, University of Milan, Via Galeazzi 4, 20161 Milano, Italy
    Autoimmun Rev 4:171-7. 2005
    ....
  60. doi Psoriatic arthritis: clinical improvement and correlation with hormone axes in etanercept-treated patients
    Fabiola Atzeni
    Rheumatology Unit, University Hospital L Sacco, Milan, Italy
    Ann N Y Acad Sci 1193:176-8. 2010
    ..However, the greater increase in serum cortisol in comparison with serum 17OHP or ASD was related to clinical improvement, which indicates that the improvement was more related to the higher cortisol levels...
  61. doi Anti-TNF therapy restores the hypothalamic-pituitary-adrenal axis
    Fabiola Atzeni
    Rheumatology Unit, University Hospital L Sacco, Milan, Italy
    Ann N Y Acad Sci 1193:179-81. 2010
    ..Long-term therapy with anti-TNF agents sensitizes the pituitary gland and improves adrenal androgen secretion, thus stimulating an alternative form of anti-inflammatory action...
  62. ncbi Antigen preparation for immunological studies in systemic autoimmune diseases
    Sandra Zampieri
    Division of Rheumatology, Department of Clinical and Experimental Medicine, University of Padova, Padova, Italy
    Ann N Y Acad Sci 1109:193-202. 2007
    ..In this review an overview of the different biochemical methods of antigen preparation and the specific methodological applications is given, also describing potential critical aspects and benefits of the different protocols...
  63. ncbi Estrogens in pregnancy and systemic lupus erythematosus
    Andrea Doria
    Division of Rheumatology, Department of Clinical and Experimental Medicine, University of Padova, Via Giustiniani, 2, 35128 Padova, Italy
    Ann N Y Acad Sci 1069:247-56. 2006
    ..This occurrence could lead to a lower-than-expected increase of IL-6, accounting for the low humoral immune response and the low disease activity observed in the third trimester of pregnancy in such patients...
  64. doi The effect of pharmacological therapy on the cardiovascular system of patients with systemic rheumatic diseases
    Fabiola Atzeni
    L Sacco University Hospital, Milan, Italy
    Autoimmun Rev 9:835-9. 2010
    ..The effects on the CV system depend on the drug itself, the dose and the period of exposure, and so CV risk should be evaluated before starting treatment with any drug...
  65. doi Detection of preclinical impairment of myocardial function in rheumatoid arthritis patients with short disease duration by speckle tracking echocardiography
    Simona Sitia
    Cardiology Unit, Department of Health Technologies, IRCCS Galeazzi Orthopedic Institute, Universita di Milano, Milan, Italy
    Int J Cardiol 160:8-14. 2012
    ..The aim of this study was to assess whether STE can be useful to detect subclinical cardiac involvement in RA patients...
  66. pmc Development and validation of the self-administered Fibromyalgia Assessment Status: a disease-specific composite measure for evaluating treatment effect
    Fausto Salaffi
    Department of Rheumatology, Polytechnic University of the Marche Medical School, Via dei Colli 52, Jesi, Ancona, Italy
    Arthritis Res Ther 11:R125. 2009
    ....
  67. ncbi Anti-cytokine antibodies for rheumatic diseases
    Fabiola Atzeni
    L Sacco University Hospital, Rheumatology Unit, Via GB Grassi 74, 20127, Milan, Italy
    Curr Opin Investig Drugs 10:1204-11. 2009
    ..This review describes the efficacy and adverse events associated with anti-cytokine treatments for autoimmune rheumatic diseases...
  68. ncbi Preclinical impairment of coronary flow reserve in patients with rheumatoid arthritis
    Fabiola Atzeni
    Rheumatology Unit, L Sacco Hospital, University of Milan, Milan, Italy
    Ann N Y Acad Sci 1108:392-7. 2007
    ..CFR is early reduced in RA patients without clinical evidence of heart disease as a result of impaired microcirculation. CFR seems a useful technique able to follow-up and to assess effects of new drugs on RA patients...
  69. doi Non-invasive assessment of coronary flow reserve and ADMA levels: a case-control study of early rheumatoid arthritis patients
    Maurizio Turiel
    Department of Health Technologies, Cardiology Unit, IRCCS Orthopedic Galeazzi Institute, University of Milan, Milano, Italy
    Rheumatology (Oxford) 48:834-9. 2009
    ....
  70. ncbi Thrombotic risk factors in primary antiphospholipid syndrome: a 5-year prospective study
    Maurizio Turiel
    Department of Cardiology, Istituto Ortopedico Galeazzi, University of Milan, Via Galeazzi 4, 20161 Milan, Italy
    Stroke 36:1490-4. 2005
    ..Because thromboembolic events are frequently observed in primary antiphospholipid syndrome (PAPS), we assessed the risk factors for new thrombotic episodes...
  71. ncbi Introduction: osteoarthritis in the third millennium: a new era for an old disease?
    Mario Carrabba
    Rheumatology Unit, L Sacco University Hospital, Milan, Italy
    Semin Arthritis Rheum 34:1-2. 2005
  72. doi Twelve years' experience with etanercept in the treatment of rheumatoid arthritis: how it has changed clinical practice
    Fabiola Atzeni
    Rheumatology Unit, L Sacco University Hospital, Milan, Italy
    Expert Rev Clin Immunol 8:213-22. 2012
    ..However, this is closely related to current RA activity and therefore suggests that it is not directly related to the drug. This article considers the published data in terms of clinical practice and changes in the progression of RA...
  73. pmc Primary and secondary autoimmune neutropenia
    Franco Capsoni
    Rheumatology Unit, Istituto Ortopedico Galeazzi, University of Milan, Milan, Italy
    Arthritis Res Ther 7:208-14. 2005
    ..Granulocyte colony-stimulating factor is a proven treatment in patients with AIN of all types and is now preferred to other possible therapies...
  74. ncbi Drug-induced lupus erythematosus
    Piercarlo Sarzi-Puttini
    Department of Rheumatology, Rheumatology Unit, L Sacco University Hospital, Via GB Grassi 74, Milan 20157, Italy
    Autoimmunity 38:507-18. 2005
    ....
  75. ncbi Systemic lupus erythematosus, atherosclerosis, and autoantibodies
    Sandra Zampieri
    Division of Rheumatology, University of Padova, Via Giustiniani 2, I 35128 Padua, Italy
    Ann N Y Acad Sci 1051:351-61. 2005
    ....
  76. doi Switching rheumatoid arthritis treatments: an update
    Fabiola Atzeni
    Rheumatology Unit, L Sacco University Hospital, Milan, Italy
    Autoimmun Rev 10:397-403. 2011
    ..However, many RA patients can be successfully treated with a second TNF antagonist, especially those discontinuing the first because of secondary failure or adverse events...
  77. doi Coronary flow reserve and asymmetric dimethylarginine levels: new measurements for identifying subclinical atherosclerosis in patients with psoriatic arthritis
    Fabiola Atzeni
    Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, London, UK
    J Rheumatol 38:1661-4. 2011
    ....
  78. ncbi Hand osteoarthritis
    Mario Fumagalli
    Rehabilitative Medicine Unit, Istituti Clinici di Perfezionamento, Milan, Italy
    Semin Arthritis Rheum 34:47-52. 2005
  79. ncbi 2nd conference on heart, rheumatism and autoimmunity, Pescara, Italy, May 19-20, 2005
    Andrea Doria
    Division of Rheumatology, University of Padova, Via Guistiniani 2, Padova 35128, Italy
    Autoimmun Rev 5:55-63. 2006
    ....
  80. pmc Combined therapeutic approach: inflammatory bowel diseases and peripheral or axial arthritis
    Fabiola Atzeni
    Rheumatology Unit, L Sacco University Hospital, Milano, Italy
    World J Gastroenterol 15:2469-71. 2009
    ....
  81. doi Resistant cases of psoriatic arthritis: how to manage them
    Fabiola Atzeni
    Rheumatology Unit, L Sacco Hospital, Milan, Italy
    J Rheumatol Suppl 83:73-5. 2009
    ..A number of clinical trials have shown that tumor necrosis factor antagonists are generally safe and efficacious in the treatment of PsA, and can inhibit the progression of radiographic damage...
  82. doi Validation of the reflux disease questionnaire for an Italian population of patients with gastroesophageal reflux disease
    Fabio Pace
    Department of Clinical Sciences, Division of Gastroenterology, L Sacco University Hospital, Milan, Italy
    Eur J Gastroenterol Hepatol 20:187-90. 2008
    ..As an English and a German version of the RDQ exist, but not an Italian one, we aimed at translating the RDQ into Italian and evaluating its reliability for the use of Italian-speaking GERD patients...
  83. ncbi Cyclic alternating pattern: a new marker of sleep alteration in patients with fibromyalgia?
    Maurizio Rizzi
    Center for Sleep and Respiratory Disorders, Rheumatology Unit, University Hospital L Sacco, Milan, Italy
    J Rheumatol 31:1193-9. 2004
    ..We evaluated the presence of CAP in patients with fibromyalgia (FM) compared to healthy controls...
  84. ncbi Validation of an Italian version of the Fibromyalgia Impact Questionnaire (FIQ-I)
    P Sarzi-Puttini
    Department of Rheumatology and Internal Medicine, University Hospital L Sacco, Milan, Italy
    Clin Exp Rheumatol 21:459-64. 2003
    ..To validate a translated Italian version of the Fibromyalgia Impact Questionnaire (FIQ)...
  85. doi IgG anti-pentraxin 3 antibodies in systemic lupus erythematosus
    N Bassi
    Division of Rheumatology, University of Padova, Via Giustiniani 2, Padua, Italy
    Ann Rheum Dis 69:1704-10. 2010
    ..To evaluate the prevalence and correlates of anti-pentraxin 3 (PTX3) antibodies in systemic lupus erythematosus (SLE)...
  86. ncbi Health-related quality of life in fibromyalgia patients: a comparison with rheumatoid arthritis patients and the general population using the SF-36 health survey
    F Salaffi
    Department of Rheumatology, Polytechnic University of Marche, Ancona, Italy
    Clin Exp Rheumatol 27:S67-74. 2009
    ..To compare health-related quality of life (HRQL) in fibromyalgia (FM) patients with that of patients with rheumatoid arthritis (RA) and the general population, and investigate if the factors are associated with the greater impact of FM...
  87. ncbi [Drug-induced lupus erythematosus]
    F Atzeni
    Unità Operativa di Reumatologia, Università Ospedale L Sacco, Milano, Italia
    Reumatismo 55:147-54. 2003
    ..Recognition of DILE is important because it usually reverts within a few weeks after stopping the drug...
  88. ncbi Autoantibody profile during short-term infliximab treatment for Crohn's disease: a prospective cohort study
    F Atzeni
    Rheumatology Unit, L Sacco University Hospital, Milan, Italy
    Aliment Pharmacol Ther 22:453-61. 2005
    ..The potential clinical implications of autoimmunity during treatment with infliximab are unclear...
  89. ncbi Lamotrigine-induced lupus
    P Sarzi-Puttini
    Rheumatology Unit, Department of Internal Medicine, University Hospital L Sacco, Milan, Italy
    Lupus 9:555-7. 2000
    ..To our knowledge, this is the first case report of an association between lamotrigine and the onset of SLE (systemic lupus erythematosus)...
  90. ncbi [Pharmacological treatment of fibromyalgia]
    M Cazzola
    U O Reumatologia, Azienda Ospedaliera L Sacco, 20157 Milano, Italia
    Reumatismo 59:280-91. 2007
    ..The results of clinical trials of anti-inflammatory medications have been generally disappointing, but three RCTs have found that tramadol (with or without acetaminophen) is effective in FM...
  91. ncbi Cardiac involvement in systemic lupus erythematosus
    A Doria
    Division of Rheumatology, University of Padua, Padua, Italy
    Lupus 14:683-6. 2005
    ..Efforts should be made to control traditional risk factors as well as all other factors which could contribute to atherosclerotic plaque development...
  92. ncbi Diet therapy for rheumatoid arthritis. A controlled double-blind study of two different dietary regimens
    P Sarzi-Puttini
    Department of Internal Medicine, University Hospital L Sacco, Milan, Italy
    Scand J Rheumatol 29:302-7. 2000
    ..To evaluate the effects of a diet therapy in patients with rheumatoid arthritis (RA)...
  93. ncbi Hypersomnolence in fibromyalgia syndrome
    P Sarzi-Puttini
    Unità Operativa di Reumatologia, Azienda Ospedaliera, Polo Universitario L Sacco, Milan, Italy
    Clin Exp Rheumatol 20:69-72. 2002
    ..To evaluate hypersomnolence in patients affected by fibromyalgia syndrome...
  94. ncbi Successful treatment of pure red cell aplasia in systemic lupus erythematosus with cyclosporin A
    F Atzeni
    Department of Rheumatology, L Sacco University Hospital, Milan, Italy
    Clin Exp Rheumatol 21:759-62. 2003
    ..The patient was successfully treated with cyclosporin A with no recurrence of the disease in the last 2 years...
  95. ncbi [Cardiovascular risk factors in systemic lupus erythematosus and in antiphospholipid syndrome]
    P Sarzi-Puttini
    Unità Operativa di Reumatologia, Azienda Ospedaliera, Polo Universitario L Sacco, Milan, Italy
    Minerva Med 94:63-70. 2003
    ..Primary and secondary APS are both associated with a significant increase of cardiovascular risk...
  96. ncbi [Early rheumatoid arthritis]
    F Atzeni
    Unita di Reumatologia, Azienda Ospedaliera Polo Universitario L Sacco, Milano, Italia
    Reumatismo 59:100-17. 2007
    ..Because the tumor necrosis factor (TNF)-alpha inhibitors have proved to stop joint damage progression in severe progressive RA, the achievement of these agents in early RA are currently of great interest...
  97. ncbi Calcium deposition and associated chronic diseases (atherosclerosis, diffuse idiopathic skeletal hyperostosis, and others)
    Fabiola Atzeni
    Rheumatology Unit, L Sacco University Hospital, Milan, Italy
    Rheum Dis Clin North Am 32:413-26, viii. 2006
    ..Serum matrix Gla protein may be a marker of osteometabolic syndromes that cause hyperostosis and plays a role in Milwaukee shoulder syndrome...
  98. ncbi A comparison of dothiepin versus placebo in the treatment of pain in rheumatoid arthritis and the association of pain with depression
    P Sarzi Puttini
    Rheumatology Service, L Sacco Hospital, Milan, Italy
    J Int Med Res 16:331-7. 1988
    ..Therapy with tricyclic anti-depressants, such as dothiepin, therefore, may determine an improvement of pain indexes besides having an anti-depressant effect...
  99. ncbi Etiopathogenetic mechanisms of fibromyalgia syndrome
    S Stisi
    Rheumatology Unit, G Rummo Hospital, Benevento, Italy
    Reumatismo 60:25-35. 2008
    ..Understanding of pathogenetic pathways in FMS has advanced beyond observing patient responses to neurophysiologically targeted therapies and basic research...
  100. ncbi Oral type II collagen in the treatment of rheumatoid arthritis. A six-month double blind placebo-controlled study
    M Cazzola
    Rheumatology Unit, Azienda Ospedaliera Polo Universitario L Sacco, Milan, Italy
    Clin Exp Rheumatol 18:571-7. 2000
    ..To evaluate the efficacy of oral chicken type II collagen (CII) in the treatment of rheumatoid arthritis (RA)...
  101. ncbi Cardiac imaging techniques in systemic autoimmune diseases
    M Turiel
    Department of Cardiology, Istituto Ortopedico Galeazzi, University of Milan, Milan, Italy
    Lupus 14:727-31. 2005
    ..More recently, other imaging modalities including magnetic resonance and computerized tomography angiography have been developed to allow imaging of the coronary arteries...